193 related articles for article (PubMed ID: 15188337)
1. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa.
Guillevin L; Mahr A; Cohen P; Larroche C; Queyrel V; Loustaud-Ratti V; Imbert B; Hausfater P; Roudier J; Bielefeld P; Petitjean P; Smadja D;
Arthritis Rheum; 2004 Jun; 51(3):482-7. PubMed ID: 15188337
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients.
Guillevin L; Lhote F; Leon A; Fauvelle F; Vivitski L; Trepo C
J Rheumatol; 1993 Feb; 20(2):289-98. PubMed ID: 8097249
[TBL] [Abstract][Full Text] [Related]
3. HBV-related cutaneous periarteritis nodosa in a patient 16 years after renal transplantation: efficacy of lamivudine.
Bedani PL; Bergami M; Cavazzini PL; Strumia R; Morelli MC; Stabellini G; Gilli P
J Nephrol; 2001; 14(5):428-30. PubMed ID: 11730280
[TBL] [Abstract][Full Text] [Related]
4. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years.
Guillevin L; Lhote F; Jarrousse B; Fain O
Ann Med Interne (Paris); 1992; 143(6):405-16. PubMed ID: 1363508
[TBL] [Abstract][Full Text] [Related]
5. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
6. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
[TBL] [Abstract][Full Text] [Related]
8. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.
Horiike N; Fazle Akbar SM; Michitaka K; Joukou K; Yamamoto K; Kojima N; Hiasa Y; Abe M; Onji M
J Clin Virol; 2005 Feb; 32(2):156-61. PubMed ID: 15653419
[TBL] [Abstract][Full Text] [Related]
9. Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients.
Guillevin L; Lhote F; Jarrousse B; Bironne P; Barrier J; Deny P; Trepo C; Kahn MF; Godeau P
Ann Med Interne (Paris); 1992; 143 Suppl 1():63-74. PubMed ID: 1363769
[TBL] [Abstract][Full Text] [Related]
10. [Polyarteritis nodosa and hepatitis B infection treated with lamivudine].
Münster T; Weis NM; Krogsgaard K
Ugeskr Laeger; 2002 Jan; 164(3):342-3. PubMed ID: 11816334
[TBL] [Abstract][Full Text] [Related]
11. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
14. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
15. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
16. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
17. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.
Bae SH; Yoon SK; Choi JY; Jang JW; Cho SH; Yang JM; Han NI; Ahn BM; Chung KW; Sun HS
J Gastroenterol Hepatol; 2005 Oct; 20(10):1527-32. PubMed ID: 16174069
[TBL] [Abstract][Full Text] [Related]
18. Treatment of polyarteritis nodosa and Churg-Strauss syndrome: indications of plasma exchanges.
Guillevin L; Lhote F
Transfus Sci; 1994 Dec; 15(4):371-88. PubMed ID: 10155556
[TBL] [Abstract][Full Text] [Related]
19. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
20. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
